SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is surging, with the community focused on its potential for a short squeeze and its progress in EU revenues. Many believe $MVST is undervalued compared to peers and anticipate a significant move upwards, fueled by positive technical indicators and upcoming earnings. The community is actively discussing its small float, low short interest, and potential for further growth.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

OMER is trending amid renewed community excitement, with many expressing anticipation for a potential short squeeze and significant upward movement. Discussions are focused on a recent deal with Novo Nordisk, with some speculating about the potential for additional news and a potential impact on the company's market capitalization. The community seems bullish, viewing OMER as undervalued in the biotech sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as the community discusses a significant price swing and potential short squeeze, with some attributing the volatility to broader sector movements and others pointing to company-specific catalysts. Bullish sentiment revolves around the company's position as a domestic antimony producer amid increasing geopolitical tensions related to rare earth mineral supply. Many are speculating about potential government support and long-term growth prospects.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as investors discuss potential catalysts, including partnerships and upcoming earnings, with a focus on PIF growth. Community members are debating the company's long-term potential against its current valuation, profitability, and the CEO's performance. Some traders are noting technical indicators and potential short squeezes, while others express concern over management and recent price action compared to peers.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling, with some community members pointing to a video from a senior advisor to President Trump as a catalyst. A trading halt and subsequent price movement in cannabis stocks have intensified the buzz, as investors discuss potential catalysts like Veterans Day. Community members are actively debating the timing and impact of any policy changes.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid escalating U.S.-China trade tensions and China's export restrictions on rare earth materials, vital for tech and defense, which are driving interest in Western producers. Community members are actively discussing potential price targets, loading up on dips, and anticipating further upside due to the increasing strategic importance of rare earth elements. Some investors believe the stock is overvalued, while others suggest the company is still undervalued, anticipating government action.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending amid discussions around a recent offering and its potential impact on the stock. While some community members express concern over dilution, others view it as a strategic move to fuel growth in the quantum computing sector, pointing to upcoming catalysts and strong backing from institutional investors. The stock's recent gains and high trading volume are also fueling the conversation.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as investors anticipate upcoming earnings results amid a boom in AI-related spending and strong demand for semiconductors. Community discussions revolve around potential earnings volatility and the overall strength of the AI infrastructure market, with some highlighting TSM's critical role as a chip supplier. Recent news points to increasing data center activity and partnerships within the AI sector, potentially boosting TSM's prospects.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to a strong earnings report and raised guidance, sparking optimism about its growth trajectory and potential profitability; the community is actively discussing the company's prospects, with some speculating about a possible buyout, fueled by increased volume and a breakout above key resistance levels.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending as community members discuss its potential due to a low float and news regarding possible trade measures impacting cooking oil. Some traders are pointing to the company's potential to move into crypto, while others highlight strong revenue despite past dilution concerns. Overall, the stock sees speculative interest driven by macro events and sector momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement PR Newswire CAMBRIDGE, Mass., Jan. 6, 2025 NeuroSense in...

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS PR Newswire CAMBRIDGE, Mass., Dec. 23, 2024...

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024...

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass., Dec. 11, 2024...

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's...

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR Newswire...

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE...

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE...

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission

NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment.
read more...

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct. 24, 2024...

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

NeuroSense Therapeutics Ltd

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$1.23
Prev Close	$1.24
Open	$1.22
Dividend Yield	0.00%
50-Day Moving Average	$1.20
Beta	0.53
Avg. Volume	1.28M
PE Ratio	-2.11

52-Week High	$2.60
52-Week Low	$0.80
Market Capitalization	$30.38M
EPS (Annual)	-$0.5489
Price to Book	11.11
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

NRSN
NeuroSense Therapeutics Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest NRSN News

NRSNNeuroSense Therapeutics Ltd